Oxurion NV OXUR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- €0.00
- Day Range
- €0.00–0.00
- 52-Week Range
- €0.00–0.01
- Bid/Ask
- €0.00 / €0.00
- Market Cap
- €1.01 Mil
- Volume/Avg
- 3.0 Mil / 107.5 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.63
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Oxurion NV is a clinical-stage biopharmaceutical company developing next-generation standard-of-care ophthalmic therapies, which are designed to improve and preserve vision in patients with retinal disorders including Geographic Atrophy (GA). The Group’s research and development facilities are located in Belgium. The Company is engaged in the development of drugs to treat blindness diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 20
- Website
- https://www.oxurion.com
Valuation
|
Metric
|
OXUR
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 0.63 |
Price/Cash Flow | — |
Price/Earnings
OXUR
Financial Strength
|
Metric
|
OXUR
|
|---|---|
Quick Ratio | 0.14 |
Current Ratio | 0.14 |
Interest Coverage | −1,052.78 |
Quick Ratio
OXUR
Profitability
|
Metric
|
OXUR
|
|---|---|
Return on Assets (Normalized) | −161.96% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −418.79% |
Return on Assets
OXUR
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Zzqrwwqcm | Kprpj | $585.2 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Mjrwtswl | Hxdcsl | $110.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Gwsqfpcqv | Mxzjl | $107.6 Bil | |
MRNA
| Moderna Inc | Fzgfcygn | Nqx | $48.2 Bil | |
BNTX
| BioNTech SE ADR | Rfsrjfy | Bmtd | $22.3 Bil | |
ARGX
| argenx SE ADR | Zhyxqpnrn | Pwpf | $21.9 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Nbrnyyggl | Hgqshzs | $19.0 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Xjzfgsdqd | Lwbtxd | $15.3 Bil | |
INCY
| Incyte Corp | Cfdpcryzb | Rbdnnm | $13.0 Bil | |
RPRX
| Royalty Pharma PLC Class A | Ppgfmpnlsd | Mdtbc | $12.8 Bil |